These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6758237)

  • 1. Immunomodulation of T cells by thymic hormone and monoclonal anti-T cell antibody.
    Bach JF; Dardenne M; Chatenoud L
    Transplant Proc; 1982 Sep; 14(3):509-12. PubMed ID: 6758237
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunosuppression by means of antilymphocyte serums in humans].
    Revillard JP
    Nouv Rev Fr Hematol; 1972; 12(2):129-37. PubMed ID: 4264610
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.
    Birkeland SA; Svendsen V; Rohr N; Hansen BL; Elbirk A; Foged N; Køhler F
    Transplant Proc; 1988 Jun; 20(3):451-4. PubMed ID: 3289183
    [No Abstract]   [Full Text] [Related]  

  • 4. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
    Bonnefoy-Berard N; Revillard JP
    J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion.
    LaCorcia G; Swistak M; Lawendowski C; Duan S; Weeden T; Nahill S; Williams JM; Dzuris JL
    Transplantation; 2009 Apr; 87(7):966-74. PubMed ID: 19352114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between CD4 and CD8 T cells determines graft outcome in monoclonal antibody-treated mice.
    Hamano K; Morris PJ; Wood KJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):792-3. PubMed ID: 8438483
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of immunomodulation on peripheral T cell subsets.
    Chatenoud L; Berrih S; Bene MC; Kreis H; Bach JF
    J Clin Immunol; 1982 Jul; 2(3 Suppl):61S-66S. PubMed ID: 6290529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to the use of antibodies for immunosuppression.
    Russell PS
    Transplant Proc; 1982 Sep; 14(3):506-8. PubMed ID: 6758236
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
    Langrehr JM; Neuhaus PJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
    [No Abstract]   [Full Text] [Related]  

  • 12. Review and preview of anti-T-cell antibodies.
    Helderman JH
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic and therapeutic applications of monoclonal antibodies to human T-cell subsets in renal transplant recipients.
    Cosimi AB
    Urol Clin North Am; 1983 May; 10(2):289-99. PubMed ID: 6344388
    [No Abstract]   [Full Text] [Related]  

  • 14. Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary?
    Renlund DG; O'Connell JB; Bristow MR
    J Heart Transplant; 1989; 8(3):191-3. PubMed ID: 2661767
    [No Abstract]   [Full Text] [Related]  

  • 15. Substantial peripheral T-cell depletion before grafting is beneficial in islet transplantation.
    Brons IG; Davies HS; Watson CJ; Cobbold SP; Waldmann H; Calne RY
    Transplant Proc; 1995 Dec; 27(6):3181. PubMed ID: 8539899
    [No Abstract]   [Full Text] [Related]  

  • 16. T-lymphocyte subsets in renal allograft recipients undergoing different immunosuppression protocols.
    Sumpio BE; Dwyer JM; Flye MW
    Curr Surg; 1986; 43(6):502-5. PubMed ID: 3542396
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience with a new monoclonal antibody in clinical kidney transplantation.
    Hillebrand G; Rothaug E; Hammer C; Illner WD; Schleibner S; Racenberg J; Gurland HJ; Land W
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1776-7. PubMed ID: 2652581
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental models in the search for new treatments of autoimmune renal diseases.
    Bach MA; Droz D
    Adv Nephrol Necker Hosp; 1980; 9():187-208. PubMed ID: 6773311
    [No Abstract]   [Full Text] [Related]  

  • 19. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation.
    Kuo YR; Huang CW; Goto S; Wang CT; Hsu LW; Lin YC; Yang KD; Chen CL; Lee WP
    J Surg Res; 2009 May; 153(2):317-25. PubMed ID: 19101689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veto cells induce long-term kidney allograft tolerance in primates without chronic immunosuppression.
    Thomas JM; Carver FM; Cunningham P; Olsen L; Thomas FT
    Transplant Proc; 1991 Feb; 23(1 Pt 1):11-3. PubMed ID: 1824966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.